|
|
|
Volumn 21, Issue 2, 2008, Pages 20-24
|
|
Indian biogenerics: An evolving industry
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA INTERFERON;
ALPHA2A INTERFERON;
BEVAC;
BIOVAC B;
ENIVAC B;
EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;
EPOFER;
EPOFIT;
ERYKINE;
ERYTHROPOIETIN;
GENE VAC B;
GENERIC DRUG;
GRANULOCYTE COLONY STIMULATING FACTOR;
GRASTIM;
HEPATITIS B VACCINE;
HUMAN GROWTH HORMONE;
HUMAN INSULIN;
INDIKINASE;
INSUGEN;
MONOCLONAL ANTIBODY;
NEUKINE;
NIMOTUZUMAB;
PEGINTERFERON;
RECOMBINANT ERYTHROPOIETIN;
RECOMBINANT HEPATITIS B VACCINE;
RECOMBINANT HUMAN INSULIN;
RECOMBINANT VACCINE;
REDITUX;
REVAC B;
RITUXIMAB;
SHANFERON;
SHANKINASE;
SHANPOIETIN;
STPASE;
STREPTOKINASE;
UNCLASSIFIED DRUG;
WEPOX;
WOSULIN;
BIOEQUIVALENCE;
BIOTECHNOLOGY;
DRUG COST;
DRUG INDUSTRY;
DRUG LEGISLATION;
DRUG MANUFACTURE;
DRUG MARKETING;
EUROPE;
GOVERNMENT;
HEAD AND NECK CANCER;
HEALTH CARE POLICY;
HEPATITIS C;
HODGKIN DISEASE;
INDIA;
NEOPLASM;
PATENT;
SCIENCE;
SHORT SURVEY;
TAX;
|
|
EID: 40949142346
PISSN: 1542166X
EISSN: None
Source Type: Journal
DOI: None Document Type: Short Survey |
|
Times cited : (2)
|
|
References (10)
|
